Cagrilintide 5mg

Coming next week

🔬 Cagrilintide — Overview

Cagrilintide is a long-acting synthetic peptide analog of amylin, developed to act as an amylin receptor agonist. It is engineered for prolonged activity and is studied primarily for its effects on appetite regulation, satiety signaling, and body-weight reduction. Cagrilintide has been investigated both alone and in combination with GLP-1 receptor agonists to enhance metabolic outcomes.

📌 Brief Functional Description

• Satiety & appetite regulation: Enhances feelings of fullness and reduces food intake via central nervous system pathways.
• Gastric emptying modulation: Slows gastric emptying, contributing to reduced post-meal intake.
• Complementary incretin effects: Studied in combination with GLP-1 agonists for additive or synergistic weight-loss signaling.
• Research relevance: Used in metabolic, obesity, and appetite-control research.

🧪 Chemical & Structural Information

🔢 CAS Number

• 2381089-78-5

🧬 Molecular Formula

• C₁₉₄H₃₀₁N₄₅O₅₉

⚖️ Molecular Weight

• ≈4,121 g/mol (Da)

🧬 Amino Acid Sequence & Structure

• Cagrilintide is a modified amylin analog with structural features that:
  • Increase protease resistance
  • Extend circulating half-life
• It includes amino-acid substitutions and lipid side-chain modification to promote albumin binding, similar to other long-acting metabolic peptides.
• The peptide remains linear and does not contain disulfide bonds.

General structural description:

Modified amylin analog with lipid side-chain acylation for prolonged systemic activity 

🧠 Mechanism & Biological Context

• Cagrilintide activates amylin receptors (heterodimers of the calcitonin receptor with RAMP proteins) in the area postrema and hypothalamus.
• Receptor activation suppresses appetite, enhances satiety signaling, and reduces caloric intake.
• When studied alongside GLP-1 receptor agonists, cagrilintide targets complementary appetite-control pathways, acting independently of insulin secretion.
• Its mechanism is central and metabolic, not stimulant-based.

⚠️ Safety & Regulatory Notes

• Investigational compound: Cagrilintide is not FDA-approved as a standalone therapeutic.
• Evaluated in clinical trials, particularly in combination therapies for weight management.
• Effects are dose- and context-dependent, consistent with amylin-based signaling.

🧪 Quick Reference